Regulation of p53 function

Experimental Cell Research

Volumn 264, Issue 1, 2001, Pages 56-66

  Woods, Douglas B ^a   Vousden, Karen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

CARCINOGENESIS; CELLULAR DISTRIBUTION; GENE ACTIVATION; GENE AMPLIFICATION; GENE CONTROL; GENE FUNCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0035835820     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2000.5141     Document Type: Article

References (136)

1. p53, guardian of the genome
2. p53, the cellular gatekeeper for growth and division
3. Maintenance of genomic integrity by p53: Complementary roles of activated and non-activated p53
4. Surfing the p53 network
5. The cellular response to p53: The decision between life and death
6. The p53-deficient mouse: A model for basic and applied cancer studies
7. Database of p53 gene somatic mutations in human tumors and cell lines
8. Regulation of p53 downstream genes
9. p53: Death star
10. Transcriptional repression by wild type p53 utilizes histone deacetylases, mediated by interaction with mSin3a
11. Wild-type p53 negatively regulates the expression of a microtubule-associated protein
12. Cell surface trafficking of Fas: A rapid mechanism of p53 mediated apoptosis
13. Death signal-induced localization of p53 protein to the mitochondria
14. Transcriptional cross talk between NF-kappaB and p53
15. Compromised HOXA5 function can limit p53 expression in human breast tumors
16. Translational regulation of human p53 gene expression
17. The ins and outs of p53
18. Nuclear localization is essential for the activity of p53 protein
19. p53 is associated with cellular microtubules and uses dynein-dependent transport for nuclear accumulation
20. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells
21. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking
22. Functions of the MDM2 oncoprotein
23. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODS
24. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6
25. Regulation and activation of p53 and its family members
26. The p53 mdm-2 autoregulatory feedback loop
27. Generation of oscillations by the p53-mdm2 feedback loop: A theoretical and experimental study
28. The loss of mdm2 induces p53 mediated apoptosis
29. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
30. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
31. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
32. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
33. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression
34. Repression of p53-mediated transcription by MDM2: A dual mechanism
35. Regulation of p53 stability by Mdm2
36. Mdm2 promotes the rapid degradation of p53
37. RING finger proteins: Mediators of ubiquitin ligase activity
38. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
39. Ubiquitin protein ligase activity of Mdm2: Differential RING finger requirements for ubiquitination and proteasomal targeting of Mdm2 and p53
40. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo
41. p300/MDM2 complexes participate in MDM2-mediated p53 degradation
42. MDM2 suppresses p73 function without promoting p73 degradation
43. WAF1/CIP1 expression by p53-independent pathways
44. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein
45. Mdm2 binds p73α without targeting degradation
46. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
47. Apoptotic and growth-promoting activity of E2F modulated by MDM2
48. Interaction between the retinoblastoma protein and the oncoprotein MDM2
49. RB regulates the stability and the apoptotic function of p53 via MDM2
50. A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2
51. The Mdm2 oncoprotein interacts with the cell fate regulator Numb
52. p53-independent role of MDM2 in TGF-β1 resistance
53. MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins
54. JNK targets p53 ubiquitination and degradation in nonstressed cells
55. Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability
56. Proteolysis by calpains: A possible contribution to degradation of p53
57. Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Try diazomethyl ketone: Evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition
58. Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus Rev protein
59. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53
60. The MDM2 RING-finger domain is required to promote p53 nuclear export
61. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation
62. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent proteins degradation and ubiquitination
63. Regulation of the specific DNA binding function of p53
64. Allosteric activation of latent p53 tetramers
65. The N-terminus of p53 regulates its dissociation from DNA
66. Conformational phenotype of p53 is linked to nuclear translocation
67. Mechanisms of switching on p53: A role for covalent modifications
68. Covalent and noncovalent modifiers of the p53 protein
69. Multisite phosphorylation and the integration of stress signals at p53
70. Regulation of p53 in response to DNA damage
71. DNA damage activates p53 through a phosphorylation-acetylation cascade
72. Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2
73. The human homologs of checkpoint kinases Chk1 and Cdsl (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites
74. Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53
75. DNA damage-inducible activation of p53 by the checkpoint kinase Chk2
76. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins
77. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DMA damage
78. Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress
79. p53 phosphorylation and association with murine double minute 2, c-Jun NH2-terminal kinase, p14ARF, and p300/CBP during the cell cycle and after exposure to ultraviolet irradiation
80. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53
81. DNA damage triggers DBR-resistance phosphorylation of human p53 at the CK2 site
82. Double-stranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53
83. Stoichiometric phosphorylation of human p53 at serine 315 stimulates p53-dependent transcription
84. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases
85. The human cdc14 phosphatase interacts with and dephosphorylates the tumor suppressor protein p53
86. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases
87. 7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro
88. Activation of p53 sequence-specific DNA binding by acetylation of the C-terminal domain
89. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage
90. Histone deacetylases specifically down-regulate p53-dependent gene activation
91. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins
92. Regulation of p53 activity in nuclear bodies by a specific PML isoform
93. The function of PML on p53-dependent apoptosis
94. PML regulates p53 acetylation and premature senescence induced by oncogenic rats
95. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1
96. SUMO-1 modification activates the transcriptional response of p53
97. c-Jun and p53 activity is modulated by SUMO-1 modification
98. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase
99. Functional interactions of p53 with poly (ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: Covalent poly (ADP-ribosyl)ation of p53 by exogenous PARP and noncovalent binding of p53 to the Mr 85,000 proteolytic fragment
100. The p53 pathway
101. Identification of redox/repair protein Ref-1 as a potent activator of p53
102. High mobility group protein-1 (HMG-1) is a unique activator of p53
103. Stress signals utilize multiple pathways to stabilize p53
104. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53
105. UV but not gamma irradiation accelerates p53-induced apopotosis in teratocarcinoma cells by repressing MDM2 transcription
106. p53-independent down-regulation of Mdm2 in human cancer cells treated with adriamycin
107. Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains
108. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53
109. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases MDM2 ability to ubiquitinate p53
110. The ARF/p53 pathway
111. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
112. Nucleolar Arf sequesters Mdm2 and activates p53
113. Identification of a cryptic nucleolar localization signal in MDM2
114. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of Mdm2 and p53
115. Two arginine rich domains in the p14ARF tumor suppressor mediate nucleolar translocation
116. Cooperative signals governing the ARF-Mdm2 interaction and nucleolar localization of the complex
117. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes
118. Regulation of the p53 protein by the MDM2 oncoprotein - Thirty-Eighth G. H. A. Clowes Memorial Award Lecture
119. Activation of p53 by oncogenes
120. ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation
121. Death associated proteins (DAPs): From gene identification to the analysis of their apoptotic and tumor suppressive functions
122. Stabilization of the MDM2 oncogene by interaction with the structurally related MDMX protein
123. MdmX protects p53 from Mdm2-mediated degradation
124. HdmX stabilizes Mdm2 and p53
125. p76 (MDM2) inhibits the ability of p90 (MDM2) to destabilize p53
126. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer
127. ARF
128. JunD protects cells from p53-dependent senescence and apoptosis
129. No requirement for src family kinases for PDGF signaling in fibroblasts expressing SV40 large T antigen
130. Control of cell cycle progression by c-Jun is p53 dependent
131. Amplification of a gene encoding a p53-associated protein in human sarcomas
132. Regulation of the cell cycle by viral oncoproteins
133. Tumor surveillance via the ARF-p53 pathway
134. Truncated form of importin alpha identified in breast cancers inhibits nuclear import of p53
135. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation
136. MDM2 oncogene as a novel target for human cancer therapy